ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2516

Adenosine Receptors Stimulate Bone Regeneration by Targeting Osteoclasts

Aranzazu Mediero1, Tuere Wilder2 and Bruce N. Cronstein3, 1Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, 2Medicine, division of Translational Medicine, NYU School of Medicine, New York, NY, 3Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adenosine receptors, orthopaedic, osteoblasts and osteoclasts

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint: Regulation of Bone Cells

Session Type: Abstract Submissions (ACR)

Background/Purpose: Various types of orthopedic procedures, including spinal fusion and repair of bone defects due to trauma, infection or metastatic disease, require formation of new bone. Adenosine, generated from the catabolism of adenine nucleotides, modulates cell function by interacting with specific cell-surface receptors (A1R, A2AR, A2BR, A3R). We have previously reported that A1R receptor blockade and A2AR stimulation inhibit osteoclast (OC) differentiation but only A2BR stimulation affects osteoblast (OB) differentiation or function. We determined whether A1R blockade, A2AR stimulation or enhancing adenosine concentrations via blockade of purine transport into cells via ent1 with dipyridamole regulates bone formation in a murine calvarial model. 

Methods: Male C57Bl/6 mice were anesthetized, a 3mm trephine defect was formed and covered with a collagen scaffold soaked in saline or 1mM adenosine receptor agonists/antagonists. Animals received appropriate treatment daily until sacrifice. At 0, 2, 4, 6 and 8 weeks calvarias were harvested and prepared for microCT and histology. XenoLight Rediject Bone Probe 680 was injected intravenously at different time points

Results: 8 weeks after surgery microCT examination of mouse calvaria demonstrate that an A1R antagonist (DPCPX), A2AR agonist (CGS21680M) or dipyridamole markedly enhances bone regeneration (77±0.2%, 60±2% and 79±2% bone regeneration, respectively, vs. 32±4% in control, p<0.001, n=5 mice per condition) whereas an A3R agonist (IB-MECA) had no effect (32±3% regeneration, n=5). In DPCPX-, CGS21680- and dipyridamole-treated mice there is increased immunostaining for osteoblast or bone formation markers (Alkaline Phosphatase, Osteocalcin and Osteonectin) in the bony defects (Alkaline Phosphatase positive cells/hpf increased from 15±1 for control to 22±1 for DPCPX, 21±1 for CGS21680 and 24±1 for Dipyridamole, p<0.001), and diminished inmunostaining for macrophages (CD163, TNfa) and osteoclasts (RANKL, RANK) in treated defects when compared to control. TRAP staining revealed fewer OCs in DPCPX-, CGS21680- and Dipyridamole-treated defects (14±1, 17±1 and 16±1 OC/hpf respectively vs. 24±1 Osteoclast/hpf for control, p<0.001) 8 weeks after defect formation. In vivo imaging with XenoLight Rediject Bone Probe 680 (a marker of bone formation) reveals a strong fluorescent signal in treated animals (DPCPX, CGS21680 and Dipyridamole) compared to control as soon as one week after bone defect formation and lasting for at least 7 weeks.

Conclusion: Inhibition of OC formation via A2AR stimulation, A1R blockade or increasing local adenosine concentration stimulates new bone formation and represents a novel approach to stimulating bone regeneration.


Disclosure:

A. Mediero,
None;

T. Wilder,
None;

B. N. Cronstein,

Canfite BioPharma,

1,

NIH, URL Pharma, OSI,

2,

Bristol-Myers Squibb, Novartis, URL, Regeneron, Gismo Therapeutics,

5,

Arthritis Foundation, SLE Foundation,

6,

Patents on use of adenosine receptor antagonists to treat or prevent fibrosis. Multiple other patents.,

.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adenosine-receptors-stimulate-bone-regeneration-by-targeting-osteoclasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology